APA

Hansen N., Ågerstam H., Wahlestedt M., Landberg N., Askmyr M., Ehinger M., Rissler M., Lilljebjörn H., Johnels P., Ishiko J., Melo J. V., Alexander W. S., Bryder D., Järås M. & Fioretos T. (20130228). SOCS2 is dispensable for BCR/ABL1-induced chronic myeloid leukemia-like disease and for normal hematopoietic stem cell function. : Leukemia.

Chicago

Hansen N, Ågerstam H, Wahlestedt M, Landberg N, Askmyr M, Ehinger M, Rissler M, Lilljebjörn H, Johnels P, Ishiko J, Melo J V, Alexander W S, Bryder D, Järås M and Fioretos T. 20130228. SOCS2 is dispensable for BCR/ABL1-induced chronic myeloid leukemia-like disease and for normal hematopoietic stem cell function. : Leukemia.

Harvard

Hansen N., Ågerstam H., Wahlestedt M., Landberg N., Askmyr M., Ehinger M., Rissler M., Lilljebjörn H., Johnels P., Ishiko J., Melo J. V., Alexander W. S., Bryder D., Järås M. and Fioretos T. (20130228). SOCS2 is dispensable for BCR/ABL1-induced chronic myeloid leukemia-like disease and for normal hematopoietic stem cell function. : Leukemia.

MLA

Hansen N, Ågerstam H, Wahlestedt M, Landberg N, Askmyr M, Ehinger M, Rissler M, Lilljebjörn H, Johnels P, Ishiko J, Melo J V, Alexander W S, Bryder D, Järås M and Fioretos T. SOCS2 is dispensable for BCR/ABL1-induced chronic myeloid leukemia-like disease and for normal hematopoietic stem cell function. : Leukemia. 20130228.